Compare ALH & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALH | ADPT |
|---|---|---|
| Founded | 1908 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.5B |
| IPO Year | 2025 | 2019 |
| Metric | ALH | ADPT |
|---|---|---|
| Price | $23.65 | $29.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $31.00 | ★ $32.57 |
| AVG Volume (30 Days) | 832.5K | ★ 2.0M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,709,237,000.00 | $276,976,000.00 |
| Revenue This Year | $6.72 | $10.85 |
| Revenue Next Year | $6.52 | $21.60 |
| P/E Ratio | $25.42 | ★ N/A |
| Revenue Growth | 13.31 | ★ 54.77 |
| 52 Week Low | $18.64 | $12.00 |
| 52 Week High | $28.23 | $32.21 |
| Indicator | ALH | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 58.55 |
| Support Level | $23.20 | $24.02 |
| Resistance Level | $25.43 | $29.92 |
| Average True Range (ATR) | 0.88 | 1.83 |
| MACD | 0.21 | 0.35 |
| Stochastic Oscillator | 56.83 | 60.05 |
Alliance Laundry Holdings Inc is a designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets. Revenue is generated through the sale of commercial-grade laundry systems and service parts across two geographic segments, North America and International, and into the three end markets of OPL, Vended, and Commercial In-Home.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.